Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab crossover trial in familial dysbetalipoproteinemia
NL-OMON49866Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of evolocumab in dysbetalipoproteinemia (DBL) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Post-fat-load non-HDL cholesterol area under the curve. Started Oct 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
dysbetalipoproteinemia (DBL)
Beyond the preview
Go deeper on NL-OMON49866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49866.